Inhibitors of anaplastic lymphoma kinase, phosphatidylinositol-3′-kinase/Akt/mammalian target of rapamycin and other molecules implicated in the pathogenesis of NB are in I/II clinical trials.[16, 17, 18] For this type of patient, it is important to examine the expression of these molecules to improve the outcome. This evidence concerns the gene MTOR and neuroblastoma.